European Clot Management Device Market To Exceed $170 Million By 2022
Improvements Over Current Standards of Care Will Drive Moderate Growth, According to Millennium Research Group
TORONTO, Sept. 4, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European market for clot management devices will see moderate growth through 2022. Although a number of segments are mature, fast-growing segments such as endovascular treatments for acute ischemic stroke (AIS) and venous thromboembolism (VTE) will support overall revenue expansion.
The neurovascular embolectomy device segment will undergo robust growth through 2022. Compared to the current standard of care, intravenous tissue plasminogen activator (IV t-PA), neuroembolectomy devices offer a longer therapeutic window after symptom onset. This is critical because AIS patients often reach the hospital beyond the time in which IV t-PA is effective. In addition, IV t-PA is ineffective for treating large clot burdens, whereas neurovascular embolectomy is fast and effective in the recanalization of large-vessel occlusions, offering an alternative treatment for these cases.
Similarly, although VTE is typically treated with anticoagulants, endovascular clot management treatment volumes for this indication will increase steadily as clinical data emerges to support the pharmacomechanical treatment of this condition, bolstering physician confidence. Additionally, there has been an increasing trend toward the combined use of percutaneous thrombectomy and catheter-directed thrombolysis (CDT), particularly for the treatment of acute cases of VTE.
"When used with CDT, thrombectomy may actually offer safety advantages compared to anticoagulants," said MRG Analyst Tony Su. "This treatment can reduce drug doses or eliminate the need for them altogether, resulting in fewer bleeding complications than with medical management. This advantage will increase adoption of percutaneous thrombectomy and CDT in the VTE indication, boosting procedure volumes and revenues."
Millennium Research Group's European Markets for Clot Management Devices 2013 reports include unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for percutaneous thrombectomy devices, embolectomy balloon catheters, CDT devices, inferior vena cava filters and neurovascular embolectomy devices in France, Germany, Italy, Spain and the United Kingdom. Supplemental country coverage is also available for Austria, Belgium, the Czech Republic, Denmark, Finland, Greece, Hungary, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland and Ukraine, as well as in aggregate for the rest of the European countries.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Millennium Research Group
More by this Source
ARRA Funding Encourages EMR Purchases at the Expense of PACS, RIS and CVIS Systems
Dec 04, 2013, 08:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.